Vanda Pharmaceuticals Inc.
VNDA
$8.81
-$0.48-5.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -220.47M | -84.20M | -66.94M | -44.25M | -18.90M |
| Total Depreciation and Amortization | 11.92M | 9.69M | 9.61M | 9.56M | 9.80M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 90.81M | -13.34M | -11.95M | -6.33M | -98.00K |
| Change in Net Operating Assets | 8.31M | 6.00M | 4.49M | -15.45M | -6.56M |
| Cash from Operations | -109.44M | -81.84M | -64.80M | -56.47M | -15.76M |
| Capital Expenditure | -998.00K | -1.11M | -1.11M | -2.44M | -4.72M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.86M | 55.10M | 45.79M | 47.13M | -12.71M |
| Cash from Investing | 94.86M | 53.99M | 44.68M | 44.69M | -17.43M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.99M | -1.51M | -989.00K | -564.00K | -155.00K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -915.00K | -915.00K | -915.00K | -915.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.91M | -2.42M | -1.90M | -1.48M | -155.00K |
| Foreign Exchange rate Adjustments | 23.00K | -199.00K | 49.00K | -100.00K | -163.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.47M | -30.48M | -21.97M | -13.36M | -33.51M |